SCHEMBL645967

SCHEMBL645967

NS(=O)(=O)c1ccc2ccccc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 3/20 0.48
NOS2 P35228 1/20 0.48
BACE1 P56817 1/20 0.48
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
LMNA P02545 2/20 0.44
CA12 O43570 3/20 0.43
CA9 Q16790 3/20 0.43
CYP1A2 P05177 1/20 0.43
CA2 P00918 4/20 0.43
CA1 P00915 3/20 0.43
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MGAM O43451 1/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28093520 0.98 NCF1 (0.47) NCF1NOS2BACE1NPC1RAB9A
Imidazole SCHEMBL3822257 0.83 ALDH1A1 (0.37) NCF1NOS2BACE1NPC1RAB9A
SCHEMBL329691 0.81 CYP1A2 (0.50) NCF1NOS2BACE1LMNACA12
SCHEMBL11679239 0.81 NCF1 (0.45) NCF1NOS2BACE1NPC1RAB9A
SCHEMBL156070 0.79 ALDH1A1 (0.48) NCF1NOS2BACE1NPC1RAB9A
SCHEMBL5609339 0.79 NCF1 (0.43) NCF1NOS2BACE1NPC1RAB9A
SCHEMBL4011347 0.79 PTGS2 (0.49) NCF1NOS2BACE1LMNACA12
SCHEMBL14194322 0.79 NCF1 (0.43) NCF1NOS2BACE1NPC1RAB9A
SCHEMBL546320 0.79 MGAM (0.47) NCF1NOS2BACE1NPC1RAB9A
SCHEMBL11679882 0.79 ALDH1A1 (0.46) NCF1NOS2BACE1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118439998-A Preparation and application of quinoline thioglycollic acid sulfonamide derivative 江苏正大清江制药有限公司 2024-08-06 CN claimed
US-20080319055-A1 Cooling Compounds GIVAUDAN SA (CH) 2008-12-25 US claimed
CN-101141890-A Cooling compounds GIVAUDAN SA (CH) 2008-03-12 CN claimed
EP-1860960-A1 COOLING COMPOUNDS Givaudan SA (CH) 2007-12-05 EP claimed
CN-1844119-A Near infrared fluorescent probe for detecting zinc ion in cell and its synthesis method and use UNIV SHANDONG NORMAL (CN) 2006-10-11 CN claimed
WO-2006099762-A1 COOLING COMPOUNDS GIVAUDAN SA (CH) 2006-09-28 WO claimed
US-5977169-A FOR TREATMENT OF A PERSON WITH AIDS OR AIDS RELATED DISEASES PHARMACIA & UPJOHN COMPANY 1999-11-02 US claimed
EP-0720607-A1 SUBSTITUTED TETRONIC ACIDS USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES PHARMACIA & UPJOHN COMPANY (US) 1996-07-10 EP claimed
WO-1995007901-A1 SUBSTITUTED TETRONIC ACIDS USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES THE UPJOHN COMPANY (US) 1995-03-23 WO claimed
EP-0602427-A1 Substituted quinolinylsulphonylureas BAYER AG (DE) 1994-06-22 EP claimed
EP-0051465-A1 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-05-12 EP claimed
CN-121818673-A Application of quinoline sulfonamide compound 昆明医科大学 2026-04-10 CN disclosed
CN-121818673-A Application of quinoline sulfonamide compound 昆明医科大学 2026-04-10 CN disclosed
CN-121735932-A Oxazoline derived tridentate N, N, N-ligand and synthesis method and application thereof 南方科技大学 2026-03-27 CN disclosed
EP-3728194-B1 QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS OTAGO INNOVATION LTD (NZ) 2025-06-04 EP disclosed
EP-0051465-B1 HERBICIDAL SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-01-16 EP disclosed
US-4453970-A Herbicidal triazinyl sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-06-12 US disclosed
US-4369320-A PLANT GROWTH RETARDERS, HERBICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1983-01-18 US disclosed
EP-0051465-A1 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-05-12 EP disclosed
EP-0051465-A1 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319055-A1 Cooling Compounds TAS2R1, TAS2R43, TAS2R3 NCF1 218/4885NOS2 2677/4885BACE1 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.